#USA #Wilmington #Lunai Bioworks #Nasdaq LNAI #Second Amended Complaint

Lunai Bioworks Issues Press Release Correction

On September 4, 2026, Lunai Bioworks, Inc. (NASDAQ: LNAI) released a correction to an earlier press announcement that was published on August 27, 2026. This update pertains to a press release where the company provided details about its expanded legal action involving naked short selling, specifically naming six broker-dealers in connection with the case.

Clarification of Changes

The adjustment made in this latest correction is minor but significant. Lunai Bioworks addressed a hyperlink error where the link directing to the Second Amended Complaint needed correction. The content of the previous release remains unchanged, meaning no new information is being disclosed regarding the case or the company's position. This ensures that all stakeholders and interested parties have access to accurate resources, especially concerning important legal documents that influence investor perceptions and company reputation.

Background of the Case

The Second Amended Complaint concerns allegations of naked short selling practices believed to have adversely impacted Lunai Bioworks' stock performance. Naked short selling involves selling shares that have not actually been borrowed or are not available for lending, which can lead to market manipulation. By naming six broker-dealers, Lunai is actively seeking to address these issues through legal channels and protect shareholder interests.

In addition to correcting the hyperlink, Lunai affirmed that all statements from the original announcement remain valid and reflect the company's ongoing commitment to transparency. This correction highlights Lunai's diligence in maintaining accurate communications to its investors, particularly in light of the serious nature of the allegations within the context of financial markets.

About Lunai Bioworks

Founded through a merger in April 2025 between Renovaro Inc. and BioSymetrics, Inc., Lunai Bioworks operates in Delaware and California. The company is pioneering a biology-first approach to drug discovery, specializing in conditions affecting the central nervous system, including Alzheimer's, Parkinson's disease, and epilepsy, among others. Its innovative AI platform, Augusta, utilizes real patient data to pinpoint disease subtypes and generate corresponding drug candidates through advanced methodologies like CRISPR technology.

Additionally, through its BioSymetrics segment, Lunai works on biodefense programs aimed at identifying and countering chemical threats. This dual focus allows Lunai to develop a robust pipeline while ensuring safety and compliance across multiple domains of scientific and technological advancements.

For interested investors and parties, the complete text of the Second Amended Complaint is available not only via the company's Investor Relations webpage but can also be found in the public docket of the U.S. District Court for the District of Delaware. Lunai’s commitment to thoroughness in its communication ensures that updates regarding legal matters are handled with the utmost awareness, reflecting the company’s responsibility to its investors and the broader community.

In conclusion, despite the correction being seemingly procedural, it embodies Lunai Bioworks' philosophy of transparency in corporate governance. Shareholders and potential investors are encouraged to keep abreast of updates, particularly as the company navigates ongoing litigation that could potentially affect its market standing and operational integrity.